Biogen is officially pivoting away from Aduhelm, the first Alzheimer's treatment the Cambridge drugmaker made in collaboration with Japanese pharma Eisai Inc., and focusing its resources on recently-approved Leqembi and other potential new Alzheimer's treatments.
One year ago, Biogen said it began a strategic review of its research and development efforts. At the time, the company was bleeding cash and said it was looking at ways to cut costs.
WATCH ANYTIME FOR FREE
 |
Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.
Copyright Boston Business Journal
